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A B S T R A C T
Optical coherence tomography (OCT) is an imaging technique extensively used for visualizing the
coronary circulation, where it assists clinical decision-making. Along with the new interventional
procedures being introduced for pulmonary vascular disease, there is an increasing need for
intravascular imaging of the pulmonary arteries. Additionally, measurements of the wall thickness of
the pulmonary arteries of patients with various types of pulmonary hypertension (PH) may provide
relevant diagnostic and prognostic information. The aim of this review is to summarize all the available
evidence on the use of OCT for imaging the pulmonary bed and to describe a simple protocol for OCT
image acquisition. We conducted a systematic review of the literature using electronic reference
databases through February 2015 (MEDLINE, Cochrane Library, Web of Knowledge, and references cited
in other studies) and the search terms ‘‘optical coherence tomography,’’ ‘‘pulmonary hypertension,’’ and
‘‘pulmonary arteries.’’ Studies in which OCT was used to image the pulmonary vessels were considered
for inclusion.We identiﬁed 14 studies reporting OCT imaging data from the pulmonary arteries. OCTwas
able to identify intravascular thrombi in patients with chronic thromboembolic PH (CTEPH), and an
increase in vessel wall thickness was found in most patients with PH, compared with the controls. OCT
has also been reported to be useful for the selection of balloon size in the setting of balloon pulmonary
angioplasty for CTEPH. Themain limitations include lack of standardization, little data on outcomes, cost,
and the technical limitations involved in visualizing small-diameter (<1 mm) pulmonary vessels. OCT
has become a potential tool for the in vivo study of vascular changes in the pulmonary arteries, and may
provide additional information in the assessment of patients with PH. Prospective high-quality studies
assessing the safety, validity, and clinical impact of OCT imaging for pulmonary vessels are warranted.
 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.Contents
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Pulmonary hypertension (PH) is not a disease per se, but a
hemodynamic and pathophysiological state that can be found in
multiple clinical conditions. It is deﬁned as an increased mean
pulmonary artery pressure (mPAP) of higher than 25 mmHg at rest,
as assessed by right heart catheterization (RHC) [1]. The revised
2013 PH clinical classiﬁcation includes ﬁve major categories with
different etiological, pathophysiological, prognostic, and thera-
peutic features [2]. While the exact causes of PH remain under
investigation, and are likely to varywith the underlying pathogenic
or genetic causes, it is widely recognized that the hallmark of all
forms of PH is structural alterations of the vascular wall [3].
Until recently, direct morphological assessment of the pulmo-
nary arteries was limited to pulmonary angiography and lung
biopsy [4]. Digital subtraction pulmonary angiography only images
the lumen, and does not provide information on wall abnormali-
ties; on the other hand, direct histological evaluation yields
valuable information on changes in pulmonary vessel walls, but
requires a thoracotomy, a potentially dangerous procedure for
patients with PH [4]. Additionally, because of the difﬁculties in
visualizing andmeasuring changes in the vascularwalls of patients
during the course of the disease, most evidence for remodeling is
derived from postmortem or postoperative specimens [5].
The rapidly developing intravascular imaging modalities, intra-
vascular ultrasound (IVUS) and optical coherence tomography
(OCT), showpromise forproviding in vivo and real-timequantitative
and qualitative descriptions of pulmonary vascular structures. IVUS
has been validated to be a reliable method for assessing the
morphology of pulmonary vessel walls, and can explore pulmonary
arteries ranging from 2 to 5 mm in diameter [4,6,7]. However, the
image resolution of IVUS is often insufﬁcient for ensuring accurate
assessment of changes in the walls of pulmonary arteries [8,9]. OCT
is a near-infrared light source-based imaging technique with a
resolution of 10–20mm, 10-fold greater than that achieved by IVUS
[10,11]. The results of several recent OCT-based studies on imaging
the pulmonary arteries suggest that it is a useful tool for the in vivo
study of the vascular remodeling process, and may have clinical
impact on the diagnosis and management of PH patients.
Additionally, with the development of new interventional modali-
ties such as balloon pulmonary angioplasty (BPA) for inoperable
chronic thromboembolic PH (CTEPH) [12–15] andpulmonary artery
denervation for pulmonary arterial hypertension (PAH) [16], the
need for intravascular imaging is increasing, andOCTmayemergeas
an important tool for guiding these procedures.
This review summarizes all the available data on the use of OCT
for imaging the pulmonary arteries.
Methods
A systematic literature search was conducted between January
2013 and February 2015. It focused on peer-reviewed originalresearch that investigated OCT imaging of the pulmonary arteries.
The search resources includedMEDLINE via PubMed, the Cochrane
Library, Web of Knowledge, and references cited in other studies.
The search employed the following terms: ‘‘optical coherence
tomography,’’ ‘‘pulmonary hypertension,’’ and ‘‘pulmonary arter-
ies.’’ The search was limited to English-language articles published
from January 2000 to February 2015. Studies in which OCT was
used to image the pulmonary vessels and with original data were
considered for inclusion. Publications that did not report original
data were excluded. Conference abstracts and results posted in
trial registries were excluded. No search of the gray literature was
performed.
Study selection was performed by the investigators E.J.
(interventional cardiologist) and R.B. (clinical cardiologist). Refer-
ences were managed using Mendeley Desktop software (V.1.12.3).
Retrieved papers were individually searched for additional
references. The citation list is available upon request. Eligible
studies included participants who underwent OCT imaging of the
pulmonary arteries (controls and patients with PH). The following
variables were extracted, when available: year of publication,
sample size, PH subgroup, diameter of imaged vessel, wall
thickness, and a summary of main ﬁndings of the study.
Grading the quality of evidence of included studies
The Effective Public Health Practice Project (EPHPP)was used to
rate the quality of evidence in the reviewed studies [17]. Each
study was assigned a grade of strong, moderate, or weak. Studies
were graded by independent reviews conducted by two of the
authors (E.J., R.B.). Studies for which the two original ratings
disagreed underwent a resolution review by a third author (P.M.).
The results are shown in Supplementary Table 1.
Results
Study selection
Of the 29 identiﬁed publications, 15 papers were excluded
because they lacked original data. Fourteen studies met the
inclusion criteria and underwent quality assessment (Fig. 1). Two
articles included OCT follow-up data [18,19]. The independent
quality assessments were in agreement in all 14 cases (3 moderate
and 11 weak). All studies were observational. The sample sizes
ranged from 1 to 124 individuals. The inner diameter of the imaged
pulmonary arterial vessels ranged from 0.98 mm [12] to 3.76 mm
[20].
OCT technical procedures for image acquisition in the pulmonary
arteries
Seven studies reported the anatomic locations of the OCT
images; OCT was performed in the inferior pulmonary lobes in all
[(Fig._1)TD$FIG]
Fig. 1. Flowchart of study search and selection process.
E. Jorge et al. / Journal of Cardiology 67 (2016) 6–148cases [8,14,20–23]. Half of studies utilized time-domain OCT
(7 studies), whereas 4 reports featured frequency-domain systems.
Three studies conducted by two different investigators described
similar methods for obtaining OCT images of the pulmonary
arteries [12,21,23]. After gaining access to a peripheral pulmonary
artery branch, they used a dedicated low-caliber occlusion balloon
catheter to occlude the target vessel, in order to remove the blood
and to obtain clear OCT images. Ringer’s lactate solution was then
infused into the artery from the distal tip of the occlusion balloon
catheter at a rate of 1 to 2 mL/s. Motorized pullback OCT imaging
was then performed at a rate of 1.0 mm/s for a length of 30 mm,
and images were acquired at 15 frames/s [23].
OCT image interpretation and measurements
Four studies from three different groups of investigators
reported the methodology used to perform measurements of the
pulmonary arterial wall thickness [18,19,21,24].
Li et al. [24] conducted a necropsy-based study of 27 normal
pulmonary artery segments taken from 11 patients who died of
trauma. OCT was performed on segments that were subsequently
processed for histological staining. The authors reported that with
OCT imaging, the pulmonary arterial wall appeared as a single
layer with homogeneous signal-rich bands. OCT-derived wall
thickness was deﬁned as the distance between the border of the
vessel wall of the lumen to the vessel wall-lung tissue interface,
and therefore encompassed the medial and intimal layers. By this
criterion, the mean wall thickness of pulmonary arteries with a
mean diameter of 2.1 mm was 0.162 mm. The correlation
coefﬁcient between wall thickness measured by OCT and by
direct histological observation was 0.837, with a mean difference
of 0.002 mm by Bland–Altman analysis, providing evidence that
wall thickness measurements by OCT are accurate [24].
Domingo et al. used IVUS and OCT during a scheduled RHC to
study 19 patients with PAH [21]. The authors assessed ‘‘intimal
ﬁbrosis,’’ which was used as a surrogate for pulmonary vascular
remodeling. In this model, ﬁbrosis appeared on OCT as intimal
thickening with high reﬂectivity, low attenuation, and a homoge-
nous signal. The authors calculated ‘‘percentage of ﬁbrosis’’ as the
difference between the area limited by the outer boundary of the
ﬁbrotic area and the luminal area, divided by the luminal cross-
sectional area. Interestingly, this study also found good correlation
between the pulmonary arterial assessment of wall ﬁbrosis by OCT
and the histological assessments of two explanted lungs, one from
a normal control participant who died of unrelated causes and one
from a patient with PAH who was undergoing pulmonary
transplantation.
Finally, Dai et al. used three morphometric parameters for
evaluating the pulmonary arterial wall: wall thickness, thickness-
diameter ratio, and wall-area ratio [19]. To calculate wall
thickness, the inner border of the vessel was delineated using
proprietary automated area software (St. JudeMedical, St Paul,MN,
USA), and the outer border was delineated semiautomatically. Amean inner diameter and a mean outer diameter were then
obtained. The difference between the inner and outer diameter
was determined for the mean vessel wall thickness. The thickness-
diameter ratio was deﬁned as the wall thickness divided by the
outer diameter. The wall-area ratio corresponded to the wall area
(whole-vessel area subtracted from the luminal area) divided by
the whole-vessel area.
OCT in pulmonary hypertension subgroups
OCT has been used for imaging of the vessel lumen and wall
abnormalities in most types of PH. A summary of the studies
reporting on OCT ﬁndings in the pulmonary arteries is presented in
Table 1.
PAH (Group 1 PH)
Five studies included patients with PAH [9,18,19,21,25]. The
feasibility of OCT imaging for a patient with PAHwas ﬁrst reported
by Hou et al. in 2010 [9]. In this pioneer study, the authors found
that the intima of the distal pulmonary artery of the PAH patient
(mean cross-sectional area 1.7 mm2) had more than twice the
thickness (0.26 mm) of the intima of the normal control (0.11 mm).
Subsequently, Tatebe et al. studied 17 patients with PAH and
5 control participants [25]. In this proof-of-concept study, the
distal pulmonary arterial media appeared to be thickened in
patients with PAH compared with the controls. Domingo et al.
reported that patients with PAH with higher cross-sectional areas
of ﬁbrosis as assessed by OCT had signiﬁcantly poorer hemody-
namics and a worse clinical prognosis than patients with less
ﬁbrosis [21]. Dai et al. recently found that OCT can reveal the
development of pulmonary arterial remodeling in patients with
‘‘borderline PH’’ (mPAP between 21 and 24 mmHg), and that there
were signiﬁcant correlations between the assessed morphometric
parameters (wall-area ratio, thickness-diameter ratio, and thick-
ness) andmPAP and pulmonary vascular resistance (PVR) [19]. The
same study conducted a follow-up OCT of 14 patients with PAH
who underwent treatment with pulmonary vasodilators, and
demonstrated the occurrence of reverse remodeling in 8 of these
patients [19]. The same group published a case report on a patient
treated with sequential combination therapy consisting of
beraprost and sildenaﬁl, whom they followed by serial OCT during
a three-year period. They documented a reduction in pulmonary
arterial wall thickness, the thickness-diameter ratio, and wall-area
ratio during treatment (Fig. 2) [18].
Pulmonary venous hypertension (Group 2 PH)
The evidence on OCT for group 2 PH, or pulmonary
venous hypertension, is particularly scarce. Our group published
a case report on a patient with severe mitral stenosis and
associated PH who underwent balloon valvuloplasty followed by
OCT of a distal segmental branch of the right pulmonary artery,
which revealed diffuse thickening of the pulmonary arterial wall
(Fig. 3B) [20].
Table 1
Summary of the published works on OCT imaging of the pulmonary arteries that are included in the systematic review.
First author and
reference
Year EPHPP
Category
n PH
subgroup
OCT
system
Anatomical
location
Diameter
of imaged
vessel
Wall
thickness
Main ﬁndings
Hou, J. [9] 2010 Weak 2 1 CTR
1 PAH
TD n/a 1.75mm
1.62mm
0.26mm
0.11mm
Intima thickness twice the control
Tatebe, S. [25] 2010 Weak 32 5 CTR
17 PAH
9 CTEPH
n/a n/a – – Media is thickened in PAH vs. controls
All CTEPH patients had thrombus
and/or luminal ﬂaps
Sugimura, K. [13] 2012 Weak 6 6 CTEPH n/a n/a – – OCT is useful for evaluating the
effectiveness of pulmonary
angioplasty
Hong, C. [12] 2012 Weak 3 3 CTEPH TD n/a 0.98–3.49mm – OCT visualizes peripheral small PA
thrombi and differentiates red from
white thrombi in vivo
Li, N. [24] 2012 Mod. 11 11 CTR TD n/a 2.14mm 0.16mm Strong correlation between histology
and OCT measurements of PA wall
thickness. PA wall has a single-layer
structure.
Hong, C. [22] 2013 Weak 1 1 CTEPH TD Segmental
right lower
lobe
– – OCT identiﬁed red thrombi in the
peripheral PA, conﬁrmed by
histology, and it may differentiate red
from white thrombi
Sugimura, K. [26] 2013 Weak 1 1 CTEPH FD n/a – – Three-dimensional OCT
demonstrates ﬂaps and meshwork in
a CTEPH patient
Tatebe, S. [8] 2013 Weak 9 9 CTEPH n/a n/a – – OCT is apparently superior to IVUS for
diagnosing CTEPH, for performing
BPA and for assessing the likelihood
of success of the procedure
Domingo, E. [20] 2013 Mod. 19 19 PAH TD n/a – – The severity of OCT wall ﬁbrosis is
related to steady and pulsatile
components of PA afterload and with
events during follow-up
Jorge, E. [23] 2013 Weak 1 1 MS FD Segmental
right lower
lobe
3.47mm
4.16mm
0.28mm
0.31mm
OCT images showed diffuse
thickening of pulmonary artery wall
Sa´nchez-
Recalde, A. [21]
2014 Weak 1 1 CTEPH FD Basal
segment
right lower
lobe
– – OCT showed multiples ﬁbrous tracts
forming a honeycomb-like structure,
with recanalized thrombosis and
intimal thickening
Roik, M. [14] 2014 Weak 1 1 CTEPH FD Segmental
left lower
lobe
OCT is useful for precisely
determining the location of target
lesion for BPA and for choosing the
appropriate balloon size and length
Dai, Z. [18] 2014 Mod. 1 1 PAH TD Segmental
middle and
right lower
lobe
3.45mm 0.28 (before Tt)
0.17 (after Tt)
OCT is useful for documenting the
regression of pulmonary arterial
remodeling in response to medical
treatment.
Dai, Z. [19] 2014 Weak 124 79 PH*
10 borderline PH
35 CTR
TD n/d – – The morphometric parameters
analyzed by OCT (PA wall thickness,
thickness-diameter ratio, and wall-
area ratio) were signiﬁcantly
correlated with mean PAP and PVR.
OCT can demonstrate the
development of PA remodeling in
borderline PH (mean PAP between
21 and 24mmHg). OCT follow-upwas
performed in 14 PAH patients,
demonstrating the occurrence of
reverse remodeling in response to
pulmonary vasodilatory treatment.
BPA, balloon pulmonary angioplasty; CTEPH, chronic thromboembolic pulmonary hypertension; CTR, control; EPHPP, Effective Public Health Practice Project; IVUS,
intravascular ultrasound; FD, frequency domain; Mod., moderate; MS, mitral stenosis; OCT, optical coherence tomography; PA, pulmonary artery; PAH, pulmonary
arterial hypertension; PAP, pulmonary artery pressure; PH, pulmonary hypertension; PVR, pulmonary vascular resistance; TD, time domain; Tt, treatment.
* PH subgroups not reported.
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Group 4 PH, or CTEPH, has also been a focus of OCT assessment
for interventional therapy using BPA, an invasive procedure being
introduced for patients with inoperable CTEPH [13]. A study that
enrolled 9 patients with CTEPH found that all had pathological
ﬁndings on OCT: 4 patients presented with occlusion of the
pulmonary artery, probably by thrombus, whereas 6 patients had
luminal ﬂaps [25]. The same investigators reported on theusefulness of OCT for accurately measuring the pulmonary arterial
luminal diameter in order to determine the size of the balloon to
use for BPA. OCT was found to bemore useful than IVUS, because it
can also predict the failure of BPA, by showing the persistence of
the occlusion of a lumen by a thrombus after inﬂation of the
balloon [8]. Roik et al. published a clinical case that also suggested
that OCT was effective at precisely locating the target lesion for
BPA and for determining the appropriate balloon size and length
[(Fig._2)TD$FIG]
Fig. 2. Serial optical coherence tomography (OCT) of the pulmonary artery duringmedical treatment. (A) The ﬁrst OCT examination (12 August 2009) showed remodeling of the
right anterior basal segmental artery, approximately 3.5 mm in diameter, which is consistent with OCT ﬁndings of intimal ﬁbrosis (mean outer diameter, 3.45 mm; outer area,
9.35 mm2;wall-area ratio, 0.302; thickness-diameter ratio, 0.081;andthickness, 0.28 mm). SerialOCTshowed thatmedical treatment induced (B)progressive improvementwith
pulmonary arterial remodeling on 25 November 2009 of the lateral segmental artery (mean outer diameter, 3.42 mm; outer area, 9.24 mm2; wall-area ratio, 0.247; thickness-
diameter ratio, 0.067; and thickness, 0.23 mm) in the rightmiddle lobe, (C) complete regressionon13August2010 in theapical segmental artery (meanouterdiameter, 3.43 mm;
outer area, 9.27 mm2; wall-area ratio, 0.202; thickness-diameter ratio, 0.052; and thickness, 0.18 mm) in the right lower lobe, and (D) sustained complete regression on
18 February 2011 in the right pulmonary artery in an undocumented speciﬁc location (mean outer diameter, 3.43 mm; outer area, 9.24 mm2; wall-area ratio, 0.187; thickness-
diameter ratio, 0.049; and thickness, 0.17 mm). (Inset) High-power image of section of pulmonary arterial wall (dashed-line box). Arrows, wall thickness.
Reproducedwithpermission fromDai et al. Visualization of complete regression of pulmonary arterial remodeling onoptical coherence tomography in a patientwith pulmonary
arterial hypertension. Circ J 2014;78:2771–3.
[(Fig._3)TD$FIG]
Fig. 3. Optical coherence tomography (OCT) images of a distal pulmonary artery (mean diameter of 2.45 mm) in the lower left lobe of a patient with mitral stenosis and
pulmonary hypertension (mean pulmonary artery pressure 26 mmHg). (A) OCT image showing a vessel wall with a single layer. (B) To increase reproducibility, the mean
vessel wall thickness can be calculated as the mean difference between the outer wall border (manually delimited) and the luminal border (automatically rendered). In this
case, the mean vessel wall thickness was 0.21 mm.
E. Jorge et al. / Journal of Cardiology 67 (2016) 6–1410
[(Fig._4)TD$FIG]
Fig. 4. Three-dimensional-optical coherence tomography (3D-OCT) imaging showed ﬂaps andmeshwork of the pulmonary arteries in a patient with chronic thromboembolic
pulmonary hypertension
Reproducedwith permission from Sugimura et al. Three-dimensional-optical coherence tomography imaging of chronic thromboembolic pulmonary hypertension. Eur Heart
J 2013;34:2121.
E. Jorge et al. / Journal of Cardiology 67 (2016) 6–14 11[14]. Sugimura et al. recently presented for the ﬁrst time three-
dimensional OCT images of the pulmonary arteries of a CTEPH
patient, clearly showing the unresolved thrombi, with the ﬂaps and
meshwork characteristic of this form of PH [26] (Fig. 4). Sa´nchez-
Recalde published OCT images from a CTEPH patient that showed
multiple ﬁbrous tracts forming a honeycomb-like structure with
recanalized thrombosis and intimal thickening [22]. The ability of
OCT to differentiate red from white thrombi in the peripheral
pulmonary artery in vivo was reported by Hong et al. in a study
involving 3 patients [23]. Using OCT signal attenuation proprieties,
the authors identiﬁed small peripheral thrombi missed by other
imaging techniques, as only erythrocytes can scatter near-infrared
light [12]. The results of the study of Tatebe et al. suggest that OCT
was useful for differentiating between the precapillary PH groups,
as all had similar hemodynamic characteristics, despite different
pathological characteristics [25].
No complications were reported in the reports that we
reviewed, which highlights the safety of OCT.
Discussion
OCT technical procedures for image acquisition in the pulmonary
arteries
All 7 studies reporting the anatomic location where OCT was
performed used the inferior pulmonary lobes. This location is in
[(Fig._5)TD$FIG]
Fig. 5. (A) Optical coherence tomography probe in the same (Fig. 3) distal pulmonary arter
(B) Pulmonary angiography of the imaged segment.accordance with previous histopathological and IVUS studies
that found more severe vascular abnormalities in the lower
lobes than in the upper lobes [27,28]. In contrast, no differences
were found between the right and left lungs in an IVUS-based
study [27].
The ﬁrst commercially available OCT system was the LightLab
M2 time-domain TD-OCT imaging system (LightLab Imaging Inc.,
Westford, MA, USA), followed by the frequency-domain FD-OCT
system (C7 XR, LightLab) [29]. FD-OCT systems have higher frame
rates and scanning speeds, enabling acquisition of pullback images
rapidly during a brief infusion of contrast. However, the diameter
of the ImageWireTM TD-OCT system is smaller (0.48 mm), a feature
that can be advantageous when exploring small vessels.
Regarding OCT technical procedures for image acquisition, our
group used a technique that does not require balloon occlusion of
the target vessel, differently from the protocols used by Domingo
et al. and Hong et al. In our protocol, the pulmonary artery is gently
catheterized by a Swan-Ganz catheter via a femoral, jugular, or
brachial approach. The Swan-Ganz catheter is then changed over
the wire to a 6-Fr Judkins right guide catheter. A 0.001400 standard
guidewire is then positioned distally in the pulmonary vessel in the
inferior pulmonary lobe, and a FD-OCT catheter (C7 Dragonﬂy
Catheter; St. Jude Medical) is advanced (Fig. 5). In order to remove
all the blood, as well as to obtain clear images, iodinated contrast is
infused at a ﬂow rate of 5 mL/s over 4 s, at 400 lb/in2 of pressure
(Medrad Mark V Provis angiographic injection system). OCTy in the lower left lobe. A 6-Fr Judkins right coronary artery guide catheterwas used.
Table 2
Protocol for optical coherence tomography imaging of the pulmonary arteries.
Before imaging
Identify the patient and target vessel in the console
Flush the OCT catheter with iodinated contrast
Connect the OCT catheter to the imaging console
Connect the OCT catheter to the motorized pullback system
Activate and verify that an image is generated before insertion
During imaging
Catheterize the pulmonary artery using a right Judkins 6 French guide
catheter
Position a 0.001400 standard guidewire distally in the pulmonary artery
through the guiding catheter
Advance the OCT catheter
Infuse iodinated contrast at a ﬂow rate of 5mL/s for 4 s, at 400psi
Scan the vessel with the integrated automated pullback device at 20mm/s
Acquire the OCT images
After imaging
Adjust calibration
Perform the measurements in the most distal vessels imaged in each lobe
Delineate the inner border of the vessel using the automated area software
and the outer border semiautomatically to measure mean vessel wall
thickness
Store the images in DICOM digital format with the same identiﬁcation
name of the angiographic images
Prepare a report that includes measurements and qualitative image
interpretation
OCT, optical coherence tomography; DICOM, Digital Imaging and Communica-
tions in Medicine.
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System (St. Jude Medical) and digitally archived. The vessel is
scanned using the integrated automated pullback device at
20 mm/s. This method uses material that is easily available from
any adult interventional cardiology catheterization laboratory, and
does not require speciﬁc low-caliber occlusion balloon catheters
(Table 2). Three-dimensional images may be obtained after
postprocessing of the cross-sectional images (Fig. 6). Morphomet-
ric assessment of the vessels can be performed ofﬂine on the
archived images.
[(Fig._6)TD$FIG]
Fig. 6. Three-dimensional optical coherence tomography images taken fromthe same
segment of the pulmonary artery (Fig. 3). Vessels sprouting from the main artery are
clearly visible. Upper panel: Three-dimensional tubular reconstruction of the vessel.
Lower panel: Three-dimensional view of the same vessel with the lumen exposed.OCT image interpretation and measurements
An important feature for consideration when analyzing OCT
images of the pulmonary arterial wall is that in contrast to the
walls of the coronary arteries, which appear as three-layered
structures, OCT images of pulmonary arteries show a single layer,
with homogeneous, signal-rich bands (Fig. 3A) [24]. Therefore, OCT
cannot clearly discriminate the intima from the media. One
possible reason for this observation is that unlike coronary arteries,
which have a media consisting of 10–20 layers of vascular smooth
muscle cells, the media of normal pulmonary arteries is
particularly rich in elastic ﬁbers, which strongly reﬂect light,
leading to a unique aspect [24]. This single-layered appearance of
the pulmonary arteries on OCT may affect the different methods
for assessing wall thickness, the hallmark of pulmonary vascular
disease. Additionally, the clinical relevance and the prognostic
impact of the concepts ‘‘medial hypertrophy’’ or ‘‘intimal ﬁbrosis’’,
which are referred to in some IVUS and OCT reports, remain
controversial. In a pivotal histopathological study conducted on
patient samples from the National Institutes of Health PAH
registry, all patients had medial hypertrophy, with most having
intimal ﬁbrosis [30]. Delgado et al., in a study that included
histopathological analysis of the pulmonary vasculature of
patients dying of advanced heart failure, found that patients with
a PVR greater than 2.5 Wood units had greater hypertrophy of the
media, compared with patients with a PVR less than 2.5 Wood
units. Neither group of patients was found to have pathologically
signiﬁcant intimal ﬁbrosis in their arteries [31]. On the other hand,
Palevsky et al. showed that only the area of intimal ﬁbrosis was
signiﬁcantly different between patients with PH who exhibited
rapid deterioration and those PH patients who remained stable on
follow-up [32]. Notably, as previously stated, IVUS cannot be used
for accurate measurement of wall thickness, because of the
strongly echogenic pulmonary arterial wall and the difﬁculty in
deﬁning the adventitial border [9,33]. The use of OCT for
differentiating the media from the intima may be challenging;
however, its ability to identify clearly the luminal and the
adventitial borders supports the argument in favor of reporting
‘‘wall thickness,’’ instead of ‘‘intimal ﬁbrosis’’ or ‘‘medial hyper-
trophy’’ [34].
Finally, because wall thickness is closely associated with vessel
diameter, the thickness-diameter ratio and the wall-area ratio
might be the most adequate parameters for representing vascular
remodeling of the pulmonary wall and for assessing patients and
controls in comparative studies and during follow-up evaluations
[35].
OCT for pulmonary hypertension subgroups
It is widely recognized that structural alterations of the
pulmonary vascular wall contribute to all forms of PH. Character-
istic features of the remodeled vasculature include increased
stiffening of the proximal elastic pulmonary arteries; thickening of
the intimal and/or medial layer of muscular arteries; development
of vaso-occlusive lesions; and the appearance of cells that express
markers speciﬁc to smooth muscle cells in normally nonmuscular
small-diameter vessels. The appearance of these cells in the walls
of nonmuscular vessels is the result of the migration and
proliferation of pulmonary arterial smooth muscle cells and
cellular transdifferentiation [3]. The ﬁnal result is that the arterial
vascular wall becomes thicker and stiffer, which changes its
behavior in terms of elasticity, pulsatility, and compliance [5].
Interestingly, there are also reports stating that these micro-
structural alterations may extend to larger pulmonary arteries
[36,37]. A recent study by Lau et al. that used IVUS to assess PAH
patients found that pulmonary arteries ranging from 2 to 5 mm in
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compared with controls. These results challenge the concept that
only pulmonary arterioles (with diameters ranging from 300 to
500 mm) are affected in PAH [36]. In accordance with previous
histopathological and IVUS studies [4–7,27,30,32,34,36], the OCT
studies of PAH patients that we analyzed also showed that the
pulmonary arterial wall appeared to be thicker, compared with
controls [9,19,25].
Regarding the prognostic impact of the intravascular imaging
techniques, several IVUS-based studies reported that the severity
of pulmonary arterial morphological changes was of no value in
predicting mortality [4,6,7]. Conversely, Domingo et al. found that
the severity of OCT-measured ‘‘intimal ﬁbrosis’’ was signiﬁcantly
negatively correlated with the capacitance of pulmonary arterial
vessels and was also predictive of unfavorable clinical outcomes
during mid-term follow-up [21]. The same study reported a
positive association between the severity of ‘‘intimal ﬁbrosis’’ and
the steady and pulsatile components of the right ventricular
afterload [21]. In support of this ﬁnding, Dai et al. demonstrated
that the pulmonary arterial wall thickness, thickness-diameter
ratio, and wall-area ratio were signiﬁcantly correlated with the
mPAP and PVR. Importantly, this latter work also demonstrated
that OCT can identify the development of pulmonary arterial
remodeling during the very early stages of PH, when themPAP is in
the range of 20–24 mmHg [19]. This ﬁnding may be important for
the management of ‘‘borderline PH’’ patients [38]. Additionally,
reverse remodeling after speciﬁc vasodilator therapywas observed
in a signiﬁcant proportion of PAH patients enrolled in an OCT
follow-up study [19]. These studies shed some light on the role of
OCT for documenting the impact of pulmonary vasodilator therapy
on vascular remodeling in patients with PAH.
The histopathological specimens of group 2 PH patients
manifest not only the expected congestive vasculopathy, but also
features compatible with pulmonary arterial disease, such as
medial hypertrophy or intimal ﬁbrosis. The classical model of this
condition is mitral stenosis [39]. Bressollette et al. used IVUS to
assess patients with mitral stenosis and PH, and found that they
had thinner pulmonary arterial walls than patients with other PH
etiologies, a ﬁnding thatmay be associatedwith a greater degree of
PH reversibility after mitral valve intervention [27]. These ﬁndings
support the concept that pulmonary arterial wall thickness can
provide relevant prognostic information.
CTEPH: a particular indication
Eight of the fourteen analyzed publications included patients
with CTEPH, which currently is the subgroup of PH patients for
whom OCT imaging has demonstrated the greatest practical
applicability. OCT has emerged as an important tool for guiding
BPA, for both precisely localizing the target lesion and determining
the correct balloon size for the procedure [13,14,25]. In theory, OCT
may have the potential for improving the efﬁcacy and safety of
BPA. Additionally, OCT demonstrates pathological manifestations
typical of this subgroup of PH, which are thrombi and luminal ﬂaps
[22,25,26], and therefore might play a role in the assessment of
speciﬁc patients for whom other imaging modalities may miss the
diagnosis [12].
Limitations of OCT
Despite the potential advantages of pulmonary arterial OCT
imagingover other available techniques, there are limitations of this
method that warrant mentioning. OCT is an invasive and expensive
technique that prolongs RHC, and, as with any other invasive
vascular technique, there are potential complications stemming
from use of a wire and catheter, such as dissection or perforation.Thus far, there have not been any reported complications associated
with the use of this technique in the pulmonary vessels.
OCT imaging needs a blood-free imaging ﬁeld, which is
achieved by transient occlusion of the proximal ﬂow through
the artery or by the injection of iodinated radiographic contrast.
These procedures may result in transient tissue ischemia;
although, since there is a rich oxygen supply to lung tissues, a
temporary occlusion of blood ﬂow to the distal pulmonary arteries
might not lead to serious complications.
OCT has limited tissue penetration (2–3 mm) and cannot fully
image large-caliber vessels. Additionally, as only case reports and
small series have been published to date, OCT still has limited
applicability in pulmonary vascular disease. Therefore, deﬁning
normal and pathological ﬁndings is difﬁcult. Finally, its clinical
prognostic impact is unclear, because robust outcome data are still
needed. Only prospective clinicopathological studies using stan-
dardized imaging methodology can help clarify the role of OCT in
the pulmonary vascular diseases.
Current clinical applications and future perspectives
With the development of new pulmonary arterial interventional
modalities, the need for intravascular imaging may also increase.
OCT may emerge as a tool for guiding these procedures. Currently,
the predominant indications for OCT imaging of the pulmonary
vessels include theassessmentofpatientswithCTEPHforBPAandas
an ancillary tool for the differential diagnosis of subgroups of PH,
namely PAH from CTEPH. Also, the use of three-dimensional OCT
rendering may facilitate image interpretation. New technologies
may enable higher frame rates, deeper penetration, faster pullbacks,
andeven theacquisitionof spectroscopicdata [40], therebyallowing
even more accurate tissue characterization.
Conclusions
OCT has arisen as a tool for the in vivo study of vascular changes
in the pulmonary arteries and may provide additional information
in the assessment of patients with PH. Currently, its main clinical
use is for CTEPH-related interventions. Prospective high-quality
studies are warranted to conﬁrm the safety, validity, and clinical
impact of OCT imaging applied to pulmonary vessels.
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